Estrogen Deprivation in Breast Cancer
| Autor: | Robert Ian Nicholson, N. Bouzubar, N. K. Rushmere, Peter Davies, Kate J. Walker, R. J. Wills, Julia Margaret Wendy Gee |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Agonist
Oncology medicine.medical_specialty Polyunsaturated Alkamides medicine.drug_class Breast Neoplasms Buserelin General Biochemistry Genetics and Molecular Biology Gonadotropin-Releasing Hormone Breast cancer History and Philosophy of Science Internal medicine Humans Medicine In patient skin and connective tissue diseases Estradiol business.industry General Neuroscience Estrogen Antagonists Cancer Antiestrogen medicine.disease Tamoxifen Cancer cell Goserelin Female Menopause business Estrogen deprivation hormones hormone substitutes and hormone antagonists medicine.drug |
| Zdroj: | Annals of the New York Academy of Sciences. 595:316-327 |
| ISSN: | 1749-6632 0077-8923 |
| DOI: | 10.1111/j.1749-6632.1990.tb34305.x |
| Popis: | The endocrinological and clinical effects of an LH-RH agonist, Zoladex, and an antiestrogen, Nolvadex, in patients with advanced breast cancer are outlined and their potential in the therapy of nonmalignant diseases of the breast and high-risk states is briefly discussed. Additional data are presented to indicate that new antiestrogens are now available for experimental studies that, unlike tamoxifen, do not possess partial estrogen-like activity and that show favorable antitumor properties against DMBA-induced mammary tumors and MCF-7 human breast cancer cells in culture. The lack of agonistic effects of this new class of pharmacological agents now allows a state of total estrogen deprivation to be approached, a previously unobtainable clinical goal. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text